The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
暂无分享,去创建一个
A. Schlicker | P. Lienau | B. Haendler | G. Siemeister | D. Moosmayer | K. Ziegelbauer | D. Mumberg | U. Lücking | P. Lejeune | B. Bader | F. von Nussbaum | S. Golfier | A. Wengner | Simon J. Baumgart | L. Wortmann | C. Schatz | M. Brands | U. Bömer | U. Eberspächer | J. Lefranc | Christoph A Schatz
[1] G. Mills,et al. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. , 2019, Cancer cell.
[2] P. Reaper,et al. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. , 2019, Journal of medicinal chemistry.
[3] Jingsong Zhang,et al. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand , 2019, Journal of Hematology & Oncology.
[4] J. Jonkers,et al. Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer , 2019, Annual Review of Cancer Biology.
[5] T. Tammela,et al. Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.
[6] A. D’Andrea. Mechanisms of PARP inhibitor sensitivity and resistance. , 2018, DNA repair.
[7] J. Nissink,et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. , 2018, Journal of medicinal chemistry.
[8] T. Conrads,et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation , 2018, The Journal of clinical investigation.
[9] E. Lecona,et al. Targeting ATR in cancer , 2018, Nature Reviews Cancer.
[10] A. Lau,et al. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression , 2018, Molecular Cancer Therapeutics.
[11] Wenjun Chang,et al. Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer , 2017, Science Signaling.
[12] Wei Zhang,et al. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. , 2017, Cell reports.
[13] S. Ramaswamy,et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells , 2017, Genes & development.
[14] Y. Bang,et al. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells , 2017, Molecular Cancer Therapeutics.
[15] L. Zeng,et al. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma , 2017, Molecular Cancer Therapeutics.
[16] Andreas Hägebarth,et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models , 2017, International journal of cancer.
[17] L. Zou,et al. Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway. , 2016, Annual review of genetics.
[18] S. Bhide,et al. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei , 2016, Molecular Cancer Therapeutics.
[19] T. Kipps,et al. ATM Mutations in Cancer: Therapeutic Implications , 2016, Molecular Cancer Therapeutics.
[20] T. Helleday,et al. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities , 2015, Cell reports.
[21] M. O’Connor,et al. Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.
[22] T. Conrads,et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo , 2015, Oncotarget.
[23] L. Karnitz,et al. Molecular Pathways: Targeting ATR in Cancer Therapy , 2015, Clinical Cancer Research.
[24] J. Palvimo,et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies , 2015, Scientific Reports.
[25] J. Nissink,et al. Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. , 2015, Future medicinal chemistry.
[26] Mickael Guedj,et al. Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.
[27] A. Aguilera,et al. Replication stress and cancer , 2015, Nature Reviews Cancer.
[28] Yan Tang,et al. A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function , 2014, Molecular Cancer Research.
[29] L. Franke,et al. ATR inhibition preferentially targets homologous recombination-deficient tumor cells , 2014, Oncogene.
[30] P. Reaper,et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 , 2014, Oncotarget.
[31] Parantu K. Shah,et al. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb–Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer , 2014, Science Signaling.
[32] F. Feng,et al. A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.
[33] H. Hieronymus,et al. Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.
[34] Alan Ashworth,et al. Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.
[35] L. Zou,et al. DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.
[36] R. Jena,et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma , 2013, Radiation oncology.
[37] B. Cornelissen,et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation , 2012, Cell Death and Disease.
[38] Peter Bouwman,et al. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.
[39] W. Mckenna,et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition , 2012, British Journal of Cancer.
[40] S. Shumway,et al. Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines , 2011, Molecular Cancer Therapeutics.
[41] B. Telfer,et al. Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft , 2011, Molecular Cancer Therapeutics.
[42] J. Glover,et al. ATR autophosphorylation as a molecular switch for checkpoint activation. , 2011, Molecular cell.
[43] P. Reaper,et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.
[44] P. Reaper,et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. , 2011, Journal of medicinal chemistry.
[45] B. Nabet,et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. , 2010, Cancer research.
[46] S. Elledge,et al. The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.
[47] Jiri Bartek,et al. An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.
[48] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[49] Kai Rothkamm,et al. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Durocher,et al. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.
[51] A. Carr,et al. The Schizosaccharomyces pombe rad3 checkpoint gene. , 1996, The EMBO journal.
[52] S. Schreiber,et al. cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[53] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .
[54] N. Curtin,et al. Targeting the DNA Damage Response for Anti-Cancer Therapy , 2018, Cancer Drug Discovery and Development.
[55] E. Taylor,et al. DNA replication stress and cancer: cause or cure? , 2016, Future oncology.
[56] M. Piccart,et al. An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.
[57] T. Fojo,et al. Mechanisms of resistance to PARP inhibitors--three and counting. , 2013, Cancer discovery.
[58] J. Haveman,et al. Clonogenic assay of cells in vitro , 2006, Nature Protocols.